ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01812746
Recruitment Status : Completed
First Posted : March 18, 2013
Last Update Posted : April 15, 2016
Sponsor:
Information provided by (Responsible Party):
BIND Therapeutics